Abstract
Purpose Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer. Patient survival prediction using machine learning and radiomics analysis proved to provide promising outcomes. However, most studies reported in the literature focused on information extracted from malignant lesions. This study aims to explore the relevance and additional value of information extracted from healthy organs in addition to tumoral tissue using machine learning algorithms.
Methods This study included PET/CT images of 154 patients collected from available online databases. The gross tumour volume (GTV) and 33 volumes of interest defined on healthy organs were segmented using nnU-Net deep learning-based segmentation. Subsequently, 107 radiomic features were extracted from PET and CT images (Organomics). Clinical information was combined with PET and CT radiomics from organs and GTVs considering 19 different combinations of inputs. Finally, different feature selection (FS, 5 methods) and machine learning (ML, 6 algorithms) algorithms were tested in a three-fold data split cross-validation scheme. The performance of the models was quantified in terms of the concordance index (C-index) metric.
Results For an input combination of all radiomics information, most of the selected features belonged to PET Organomics and CT Organomics. The highest C-Index (0.68) was achieved using univariate C-Index FS method and random survival forest ML model using CT Organomics + PET Organomics as input as well as minimum depth FS method and CoxPH ML model using PET Organomics as input. Considering all 17 combinations with C-Index higher than 0.65, Organomics from PET or CT images were used as input in 16 of them.
Conclusion The selected features and C-Indices demonstrated that the additional information extracted from healthy organs of both PET and CT imaging modalities improved the machine learning performance. Organomics could be a step toward exploiting the whole information available from multimodality medical images, contributing to the emerging field of digital twins in healthcare.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Euratom research and training programme 2019-2020 Sinfonia project under grant agreement No 945196.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.cancerimagingarchive.net/collection/nsclc-radiogenomics
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available online at: https://www.cancerimagingarchive.net/collection/nsclc-radiogenomics/
https://www.cancerimagingarchive.net/collection/nsclc-radiogenomics/
